GLP-1 class medications, widely recognized by brand names such as Ozempic and Mounjaro, may offer benefits beyond weight reduction, potentially alleviating asthma symptoms in individuals with obesity. This significant conclusion was drawn by researchers from the University of Aberdeen and the Observational and Pragmatic Research Institute (OPRI) in Singapore, following an in-depth analysis of data from over 60,000 patients. The groundbreaking findings were subsequently published in the esteemed journal *Advances in Therapy*.
The research team conducted a comprehensive comparison of asthma severity indicators over a one-year period, examining patients who were receiving GLP-1 medications against a control group not on these drugs. The study`s results revealed a notable trend: patients on GLP-1 experienced a significant reduction in the prescription of steroids and other conventional asthma control medications. Remarkably, these improvements were observed even with an average weight loss of a modest 0.9 kilograms, suggesting an effect beyond mere weight reduction.
The proposed mechanism of action for these benefits is thought to be intrinsically linked to the anti-inflammatory properties of GLP-1, which critically differ from those characteristic of traditional steroid medications. This distinction is particularly vital for patients who suffer from both obesity and asthma, as this demographic often exhibits a suboptimal or poorer response to standard, conventional treatments for their respiratory condition.
In light of these findings, the study authors strongly suggest that GLP-1 medications should be considered a promising potential tool for the comprehensive management of respiratory conditions, especially in the context of co-morbid obesity. Further rigorous clinical trials are anticipated and highly recommended to more precisely evaluate and confirm their full therapeutic capabilities and efficacy specifically in asthma therapy.
It is worth noting that previously, semaglutide-based drugs, which are widely employed for both diabetes management and weight loss, have also been associated with improved outcomes in severe neurological events such as stroke and cases involving traumatic brain injury, further highlighting the diverse therapeutic potential of this drug class.
Disclaimer: This article summarizes scientific research. Always consult with a healthcare professional for medical advice and before making any decisions related to your health or treatment.
